Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 143 results for sclerosis

  1. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

  2. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

  3. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  4. Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (HTG501)

    Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.

  5. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

  6. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

  7. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

  8. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

  9. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  10. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

  11. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  12. Percutaneous laser therapy for fetal tumours (HTG118)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

  13. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  14. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  15. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.